Tact.ai

Name: Tact.ai
Brand: Aktana
Rating: 4.2 (59 reviews)

Now part of PharmaForceIQ | Intelligent Customer Engagement for Life Sciences Teams

Est 2008|Valuation $150M|Raised $203.8M

LinkedIn 19K|Website|Web traffic 3K|FTEs 122|HQ San Francisco, California, US

01Competitive Landscape

Narrative analysis

- **Aktana** is the most direct continuation because it acquired the Tact.ai technology and productized it as Aktana Copilot. For buyers, this may mean the capabilities formerly labeled "Tact.ai" are now accessed through Aktana. - **Veeva** is a widely used life sciences CRM ecosystem; it often wins where customers require an end-to-end compliant platform with strong industry fit, even if cost and implementation complexity are considerations. - **Salesforce** functions both as a CRM foundation and as a provider of AI features; however, life sciences-specific requirements can keep Veeva and specialized vendors relevant for many buyers.

Market adoption signals

Aktana states that a large number of commercial and medical teams use its engine and that a significant portion of the world’s largest pharmaceutical companies are customers. These are vendor claims and should be verified through customer references and third-party validation.

	Tact.ai (tact.ai)	Aktana (Aktana Copilot / field intelligence)	Veeva (Veeva CRM / Vault CRM ecosystem)
Starting Price	Not publicly listed (contact sales)	Not publicly listed (enterprise)	Not publicly listed (enterprise); published per-user subscription pricing available from the vendor
Suitable for	Teams seeking conversational and mobile CRM workflow assistance; historically Salesforce-adjacent	Life sciences omnichannel execution and recommendation workflows; now includes the acquired conversational layer	Life sciences CRM and compliant multichannel engagement at scale
Strengths	Mobile-oriented workflow and activity logging focus; emphasis on usability	Life sciences specialization; omnichannel orchestration and recommendation engines; includes acquired conversational capabilities	Deep vertical feature set for life sciences, regulatory alignment, and content management
Weaknesses	Limited transparent current-state information post-acquisition; older reviews; performance and integration complaints in historical reviews	Enterprise implementation complexity; pricing and implementation may be significant; data and adoption dependencies	Perceived cost and vendor lock-in; complex implementations and long deployment cycles

01Competitive Landscape

Narrative analysis

Aktana is the most direct continuation because it acquired the Tact.ai technology and productized it as Aktana Copilot. For buyers, this may mean the capabilities formerly labeled "Tact.ai" are now accessed through Aktana.
Veeva is a widely used life sciences CRM ecosystem; it often wins where customers require an end-to-end compliant platform with strong industry fit, even if cost and implementation complexity are considerations.
Salesforce functions both as a CRM foundation and as a provider of AI features; however, life sciences-specific requirements can keep Veeva and specialized vendors relevant for many buyers.

Market adoption signals

Aktana states that a large number of commercial and medical teams use its engine and that a significant portion of the world’s largest pharmaceutical companies are customers. These are vendor claims and should be verified through customer references and third-party validation.

	Tact.ai (tact.ai)	Aktana (Aktana Copilot / field intelligence)	Veeva (Veeva CRM / Vault CRM ecosystem)
Starting Price	Not publicly listed (contact sales)	Not publicly listed (enterprise)	Not publicly listed (enterprise); published per-user subscription pricing available from the vendor
Suitable for	Teams seeking conversational and mobile CRM workflow assistance; historically Salesforce-adjacent	Life sciences omnichannel execution and recommendation workflows; now includes the acquired conversational layer	Life sciences CRM and compliant multichannel engagement at scale
Strengths	Mobile-oriented workflow and activity logging focus; emphasis on usability	Life sciences specialization; omnichannel orchestration and recommendation engines; includes acquired conversational capabilities	Deep vertical feature set for life sciences, regulatory alignment, and content management
Weaknesses	Limited transparent current-state information post-acquisition; older reviews; performance and integration complaints in historical reviews	Enterprise implementation complexity; pricing and implementation may be significant; data and adoption dependencies	Perceived cost and vendor lock-in; complex implementations and long deployment cycles

Tact.ai

01Competitive Landscape

Narrative analysis

Market adoption signals

02Market Map

01Competitive Landscape

Narrative analysis

Market adoption signals

02Market Map